
- Pharmaceutical Technology-10-02-2018
- Volume 42
- Issue 10
Understanding Internal Release Limits
Internal release limits help ensure that a batch of drug product remains within specifications throughout its shelf life. This article explores what internal release limits are and why they are important.
The manufacture of pharmaceutical and biopharmaceutical drug products is a complex process that takes place in a highly regulated environment (1). Success requires a combination of scientific, engineering, and regulatory knowledge. One critical part of drug development is formulating the compound into a final drug product, ensuring that desirable physical and chemical properties remain stable for an acceptable period of time and meet regulatory and commercial requirements for specifications for the product (2).
One key requirement is that the drug retain its physical and chemical properties such as potency, purity, and bioavailability for a set period of time, referred to as its shelf life (3). Once a shelf life has been defined for the drug, control strategies must be instituted to provide a high level of assurance that batches of drug product released into the market remain within specifications throughout the drug’s shelf life.
One critical control strategy is the use of internal release limits. This article discusses how these limits are calculated and applied to ensure drug product quality. Click
to view a PDF of this article.
Peer-Reviewed
Submitted: May 29, 2018
Accepted: June 19, 2018
About the Authors
Mary Ann Gorko* is technical manager of statistics at AstraZeneca, maryann.gorko@astrazeneca.com; Stan Altanis senior director at Janssen Pharmaceutical R&D; Yilje Dong is an independent consultant; Niels Vaever Hartvig is principal big data analyst at Novo Nordisk A/S; Mark Johnson is senior principal statistician at AbbVie’s research department; Gregory Larner is manager of statistics at Pfizer; and Stacy Sherling is research scientist at Eli Lilly.
*To whom all correspondence should be addressed.
Article Details
Pharmaceutical Technology
Vol. 42, No. 10
October 2018
Pages: 30, 32, 34, 36, 38–39
Citation
When referring to this article, please cite it as S. Altan, Y. Dong, M.A. Gorko, N. V. Hartvig, M. Johnson, G. Larner, and S. Sherling, "Understanding Internal Release Limits," Pharmaceutical Technology 42 (10) 2018.
Articles in this issue
about 7 years ago
Drug Delivery Innovation Funded by the Gates Foundationabout 7 years ago
New Dose Forms Focus on the Patientabout 7 years ago
Protecting Solid-Dose Shelf Lifeabout 7 years ago
Considering Twin-Screw Granulationabout 7 years ago
Optimizing Containment in OSD Manufacturingabout 7 years ago
Developing Lipid-Based Formulationsabout 7 years ago
Efficiency Demands Drive Advances in API Labsabout 7 years ago
AAPS Traces the Path to ICH M10about 7 years ago
Outsourcing Development: Small-Scale to CommercialNewsletter
Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.





